Mission Statement

Pharmos Corporation is a bio-pharmaceutical company focused on the discovery, development and commercialization of therapeutics for the central and peripheral nervous systems, and ophthalmologic, cardiovascular and inflammation-related indications.

Pharmos uses state-of-the-art drug design, synthesis, screening, and delivery methodologies to improve targeted molecules and enhance their therapeutic benefits. Pharmos is committed to developing drugs with superior safety and efficacy.

Company Profile

Driven by its mission to develop drugs with superior safety and efficacy, Pharmos uses advanced methods of drug design, combinatorial chemistry and screening tools to invent new and to improve existing therapeutic compounds. Pharmos’ proprietary technologies have resulted in products that have increased efficacy and/or reduced side effects relative to their precursors and to competing products.

Pharmos has successfully developed and commercialized two proprietary ophthalmic products, Lotemax® and Alrex®. A third ophthalmic product, Loteprednol Etabonate-Tobramycin (LE-T), is completing advanced clinical development.

Pharmos is developing dexanabinol (HU-211) for traumatic brain injury (TBI). In Phase II clinical trials with severe TBI patients, dexanabinol has demonstrated excellent results. A multinational pivotal study is underway in Europe and is anticipated to commence in the U.S. later this year.

Pharmos scientists are actively developing analogs of dexanabinol to exploit the distinctive neuroprotective and anti-inflammatory properties of this family of compound. Pre-clinical programs are examining the use of these analogs in diseases such as: Stroke, Myocardial Infarction (Heart Attack), Multiple Sclerosis and neuropathic pain.

Using its platform technology, Pharmos is also developing Selective Estrogen Receptor Modulators (SERMs). These compounds are screened for use in a variety of indications including cancer, osteoporosis and cardiovascular disease.

Pharmos has developed proprietary and novel lipid-based Drug Delivery Systems (DDS), the Emulsome and the SME, with a wide range of therapeutic applications for a variety of drugs that are delivered by parenteral, dermal or oral routes of administration.